About BioMarker Strategies
BioMarker Strategies is a Healthcare company based in Rockville (United States) founded in 2007. Cancer diagnostics systems are developed for solid tumor predictive testing. BioMarker Strategies has raised $7.25 million across 14 funding rounds from investors including HHS, National Cancer Institute and NIH SBIR/STTR. BioMarker Strategies offers products and services including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, Natera and Denali Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
BioMarker Strategies was founded in 2007 in Rockville, United States, within the biotechnology sector focused on oncology. Cancer diagnostics systems, including SnapPath, are developed to enable predictive tests that guide targeted drug development and treatment selection for patients with solid tumor malignancies. PathMAP functional signaling profiles are generated using this system, serving as biomarker tests to predict individual responses to targeted therapies.
- Headquarters Rockville, United States
- SectorsHealthcare
- Email••••••••
- Website biomarkerstrategies.com
- Social LinkedIn Facebook
- Total Equity Funding$7.25M (USD)
in 14 rounds
- Latest Funding Round$299.34K (USD), Grant
Sep 2017
- InvestorsHHS
& 3 more
Products & Services of BioMarker Strategies
BioMarker Strategies offers a comprehensive portfolio of products and services, including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles.
Automates profiling of live tumor cells for predictive cancer treatment selection.
Generates predictive profiles from live cells for targeted therapy responses.
Funding Insights of BioMarker Strategies
BioMarker Strategies has successfully raised a total of $7.25M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $299.34 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.25M
- Total Rounds 14
- Last Round Grant — $299,340
- First Round $290,000
(Jun 2008)
- Investors Count 4
Latest 10 of 14 funding rounds of BioMarker Strategies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $299,340 | Grant | – | – | |
| Aug 2016 | $525,000 | Series A | – | – | – |
| Jul 2016 | $2.3M | Grant | – | – | |
| Sep 2015 | $2.28M | Grant | – | – | |
| Nov 2013 | $125,000 | Series A | – | – | – |
| Sep 2013 | $1.5M | Grant | – | – | |
| Sep 2011 | $200,000 | Grant | – | – | |
| Aug 2011 | $2.33M | Series A | – | – | – |
| Apr 2011 | $1M | Grant | – | – | |
| Aug 2010 | $2.01M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in BioMarker Strategies
BioMarker Strategies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Provides grants and investments to support health, education, and community development in Baltimore. | 1953 | abell.org | Baltimore, United States |
Investor details for BioMarker Strategies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioMarker Strategies
3 people are tracked at BioMarker Strategies (1 in leadership, 2 in board & advisors).
| Name | Role | Group |
|---|---|---|
Jerry Parrott | President & CEO | Leadership |
Glenn Miller | Chair of the Scientific Advisory Board and a Director, BioMarker Strategies | Board & advisors |
Katarzyna Kusmierz | Chairman of the Supervisory Board | Board & advisors |
Complete people profiles for BioMarker Strategies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioMarker Strategies
3 dated milestones of BioMarker Strategies across 10 years, from founding to its latest funding, stage changes and deals.
- Founded BioMarker Strategies is founded.
- Funding First funding round of $290K.
- Funding Latest funding round, Grant, of $299K.
Competitors of BioMarker Strategies
BioMarker Strategies has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Denali Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. |
Detailed competitors of BioMarker Strategies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BioMarker Strategies (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomarker Strategies
Complete news archive for BioMarker Strategies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMarker Strategies
BioMarker Strategies was founded in 2007 and raised its 1st funding round 1 year after it was founded.
BioMarker Strategies is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
BioMarker Strategies is a funded company, having raised a total of $7.25M across 14 funding rounds to date. The company's 1st funding round was a Seed of $2.01M, raised on Jun 2008.
BioMarker Strategies was founded in 2007 in Rockville, United States, within the biotechnology sector focused on oncology. Cancer diagnostics systems, including SnapPath, are developed to enable predictive tests that guide targeted drug development and treatment selection for patients with solid tumor malignancies. PathMAP functional signaling profiles are generated using this system, serving as biomarker tests to predict individual responses to targeted therapies.
BioMarker Strategies's top competitors include Guardant Health, Natera and Denali Therapeutics.
BioMarker Strategies offers SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles.
BioMarker Strategies has 4 investors. Key investors include HHS, National Cancer Institute, NIH SBIR/STTR, and Abell Foundation.